Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
SPECT Imaging of [99mTc]Tc-BQ0413 in Prostate Cancer
NCT06101927Phase 1Completed
- Sponsor
- Tomsk National Research Medical Centre of the Russian Academy of Sciences
- Start
- Oct 2023
- Primary completion
- May 2024
- Modality
- Peptide-Drug Conjugates
- Countries
- 1
01
Overview
Phase 1, open-label trial of [99mTc]Tc-BQ0413 in prostate cancer (PCa) (2 arms), sponsored by Tomsk National Research Medical Centre of the Russian Academy of Sciences. Primary endpoints: Gamma camera-based whole-body [99mTc]Tc-BQ0413 uptake value at 24 hours, SPECT-based [99mTc]Tc-BQ0413 value in tumor lesions at 6 hours and 2 more. Started Oct 2023; status: completed.
02
Drugs
[99mTc]Tc-BQ0413
03
Conditions
prostate cancer (PCa)
Beyond the preview
Go deeper on NCT06101927.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06101927.